Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926783 · ClinicalTrials.gov registry record · Phase 4
Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation, sponsored by Biosense Webster.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
- 7
- Study locations
NCT00926783: Completed Phase 4 study of Atrial Fibrillation, sponsored by Biosense Webster.
NCT00926783 is a Phase 4 study of Atrial Fibrillation that has completed, run by Biosense Webster. The registered enrollment target is 86 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00926783, a Phase 4 study of Atrial Fibrillation, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will be a multicenter, open, prospective, randomized trial. Patients with either paroxysmal or persistent atrial fibrillation will be considered for the study. (For US, only paroxysmal atrial fibrillation will be considered.) Eligible subjects will be randomized into one of two arms in the study: (1) targeted CFAE ablation or (2) generalized CFAE ablation. Both techniques will then be followed by PVAI (pulmonary vein antral isolation) as part of a hybrid ablation strategy. The nature of the ablation procedures does not allow physicians to be blinded to the randomization.
Primary Outcome
Proportion of subjects who were free from atrial arrhythmia (no recurrence of atrial fibrillation, atrial flutter, and atrial tachycardia (AF/AFL/AT)) between Day 91 and Day 365 post first ablation procedure.
Conditions Studied
Interventions
- PROCEDURE CFAE ablation
Study Locations (7)
Ontario
- Hamilton Health Sciences Centre - Hamilton
- Southlake Regional Health Center - Newmarket
Quebec
- Montreal Heart Institute - Montreal
- Hopital Laval - Institut universitaire de cardiologie et de pneumonologie - Québec
Illinois
- Loyola University Medical Center - Maywood
Maryland
- Johns Hopkins University - Baltimore
South Australia
- Royal Adelaide Hospital - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
What the finished NCT00926783 record still lists
NCT00926783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CFAE ablation is the first listed.
NCT00926783 lists 7 locations in 5 states (Ontario, Quebec, Illinois).
Frequently Asked Questions
What is clinical trial NCT00926783 about?
NCT00926783 is a clinical study titled "Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation". This study will be a multicenter, open, prospective, randomized trial. Patients with either paroxysmal or persistent atrial fibrillation will be considered for the study. (For US, only paroxysmal atrial fibrillation will be considered.) Eligible subjects will be randomized into one of two arms in th...
What is the current status of trial NCT00926783?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2009-08. Estimated completion is 2013-09.
What conditions does trial NCT00926783 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00926783?
The interventions under investigation include: CFAE ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00926783?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00926783 being conducted?
This trial has 7 study locations across Illinois, Maryland, South Australia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00926783's enrollment target sits among peer trials
86 148th of 202 higher than 55 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia